In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.